ArticleScience (New York, N.Y.)2020
Feasibility of blood testing combined with PET-CT to screen for cancer and guide intervention.
Open access · greenAbstract read
In one paragraph
Article in Science (New York, N.Y.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 360 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
360citing papers in PubMed, 1 pooled it
43.8field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
360 citing papers in PubMed, 1 synthesis or guideline pooled it, 644 citations in OpenAlex.
- Multi-cancer early detection tests for general population screening: a systematic literature review.Health technology assessment (Winchester, England) · 2025Pooled it
- Real-time evaluation and adaptation to facilitate rapid recruitment in a large, prospective cohort study.BMC health services research · 2024Trial
- Pulmonary nodules: classification, biomarkers, signaling pathways, diseases, early diagnosis and management.Signal transduction and targeted therapy · 2026Review
- The Vanguard Study: Assessing feasibility of conducting randomized trials of novel multi-cancer detection tests.Contemporary clinical trials · 2026Article
- Liquid biopsy for early detection of pancreatic ductal adenocarcinoma.Nature medicine · 2026Article
- Design, Construction, and Application of Implantable Fiber Biosensors.Advanced materials (Deerfield Beach, Fla.) · 2026Review
- Beyond Detection Limits: Integrated Biosensors for Molecular Diagnostics, Longitudinal Monitoring, and Clinical Translation.Biosensors · 2026Review
- Progress, challenges, and future directions of pancreatic cancer surveillance in high-risk populations.Communications medicine · 2026Review
- Applications of Artificial Intelligence in Cancer Diagnosis and Treatment.Cancer medicine · 2026Review
- Multifeature sequencing-based liquid biopsy for cancer diagnosis and monitoring.Genome medicine · 2026Review
- Paired Capillary and Venous Serum Specimen Agreement for Protein Biomarker Measurements and Risk Category Outputs in a Multi-Cancer Early Detection Tool.Diagnostics (Basel, Switzerland) · 2026Article
- Review
- Liquid biopsy-based multi-omics approach for early detection of hepatocellular carcinoma (ASCEND-Hep): a multiphase prospective development and validation study.BMC medicine · 2026Article
- Diagnostic Implications of Multi-Cancer Early Detection Testing in the Investigation of Cancer Symptoms: An Exploratory Retrospective Analysis of the SYMPLIFY Study.The Lancet regional health. Europe · 2026Article
- Individualised progesterone receptor modulator prevention strategies for triple-negative breast cancer in BRCA1 pathogenic variant carriers.NPJ breast cancer · 2026Review
- Molecular Cancer Signal Localization in MCED Testing Minimizes Radiation and Imaging Burden Compared with Whole-body Imaging Approaches.Cancer prevention research (Philadelphia, Pa.) · 2026Article
- Benchmarking reliability and calibration of LLMs for multi-cancer early detection test communication.JAMIA open · 2026Article
- Advances in translational lung cancer research in 2025: a narrative review.Translational lung cancer research · 2026Review
- Article
- Clinical development of molecular residual disease (MRD) and multi-cancer early detection (MCED) using liquid biopsy multiomics with artificial intelligence (AI).International journal of clinical oncology · 2026Article
300 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
- Commented on by
Authors and funding
40 authors at 5 institutions in 1 country.
Anne Marie Lennon *Department of Oncology, the Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine, 733 N. Broadway, Baltimore, MD 21205, USA.ORCID 0000-0001-8957-3945
Adam H Buchanan *Geisinger, 100 N. Academy Avenue Danville, PA 17822, USA.ORCID 0000-0002-6518-2453
Isaac Kinde *Thrive Earlier Detection Corp., 38 Sidney Street Cambridge, MA 02139, USA.
Andrew Warren *Thrive Earlier Detection Corp., 38 Sidney Street Cambridge, MA 02139, USA.ORCID 0000-0003-1948-0289
Ashley Honushefsky *Geisinger, 100 N. Academy Avenue Danville, PA 17822, USA.ORCID 0000-0002-8389-0218
Ariella T CohainThrive Earlier Detection Corp., 38 Sidney Street Cambridge, MA 02139, USA.ORCID 0000-0003-2375-0683
David H LedbetterGeisinger, 100 N. Academy Avenue Danville, PA 17822, USA.ORCID 0000-0001-8934-4210
Fred SanfilippoDepartment of Pathology and Laboratory Medicine, Emory University School of Medicine, 100 Woodruff Circle Atlanta, GA 30322, USA.ORCID 0000-0001-5302-0521
Kathleen SheridanGeisinger, 100 N. Academy Avenue Danville, PA 17822, USA.
Dillenia RosicaGeisinger, 100 N. Academy Avenue Danville, PA 17822, USA.ORCID 0000-0002-8405-2857
Christian S AdonizioGeisinger, 100 N. Academy Avenue Danville, PA 17822, USA.
Hee Jung HwangThrive Earlier Detection Corp., 38 Sidney Street Cambridge, MA 02139, USA.ORCID 0000-0002-0337-2323
Kamel LahouelDepartment of Oncology, the Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine, 733 N. Broadway, Baltimore, MD 21205, USA.
Joshua D CohenDepartment of Oncology, the Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine, 733 N. Broadway, Baltimore, MD 21205, USA.ORCID 0000-0003-1158-5668
Christopher DouvilleDepartment of Oncology, the Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine, 733 N. Broadway, Baltimore, MD 21205, USA.ORCID 0000-0002-2510-4151
Aalpen A PatelGeisinger, 100 N. Academy Avenue Danville, PA 17822, USA.ORCID 0000-0001-7554-3286
Leonardo N HagmannThrive Earlier Detection Corp., 38 Sidney Street Cambridge, MA 02139, USA.
David D RolstonGeisinger, 100 N. Academy Avenue Danville, PA 17822, USA.ORCID 0000-0002-8707-949X
Nirav MalaniThrive Earlier Detection Corp., 38 Sidney Street Cambridge, MA 02139, USA.ORCID 0000-0002-4218-0551
Shibin ZhouDepartment of Oncology, the Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine, 733 N. Broadway, Baltimore, MD 21205, USA.ORCID 0000-0003-1941-4425
Chetan BettegowdaDepartment of Oncology, the Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine, 733 N. Broadway, Baltimore, MD 21205, USA.
David L DiehlGeisinger, 100 N. Academy Avenue Danville, PA 17822, USA.
Bobbi UrbanThrive Earlier Detection Corp., 38 Sidney Street Cambridge, MA 02139, USA.ORCID 0000-0003-2516-3730
Christopher D StillGeisinger, 100 N. Academy Avenue Danville, PA 17822, USA.ORCID 0000-0001-8006-8483
Lisa KannThrive Earlier Detection Corp., 38 Sidney Street Cambridge, MA 02139, USA.ORCID 0000-0002-3350-0963
Julie I WoodsGeisinger, 100 N. Academy Avenue Danville, PA 17822, USA.
Zachary M SalvatiGeisinger, 100 N. Academy Avenue Danville, PA 17822, USA.
Joseph VadakaraGeisinger, 100 N. Academy Avenue Danville, PA 17822, USA.ORCID 0000-0002-5796-0737
Rosemary LeemingGeisinger, 100 N. Academy Avenue Danville, PA 17822, USA.ORCID 0000-0001-9492-5407
Prianka BhattacharyaGeisinger, 100 N. Academy Avenue Danville, PA 17822, USA.
Carroll WalterGeisinger, 100 N. Academy Avenue Danville, PA 17822, USA.ORCID 0000-0003-2532-0564
Alex ParkerThrive Earlier Detection Corp., 38 Sidney Street Cambridge, MA 02139, USA.ORCID 0000-0003-1278-6680
Christoph LengauerThrive Earlier Detection Corp., 38 Sidney Street Cambridge, MA 02139, USA.
Alison KleinDepartment of Oncology, the Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine, 733 N. Broadway, Baltimore, MD 21205, USA.ORCID 0000-0003-2737-8399
Cristian TomasettiDepartment of Oncology, the Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine, 733 N. Broadway, Baltimore, MD 21205, USA.ORCID 0000-0003-3277-4804
Elliot K FishmanDepartment of Oncology, the Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine, 733 N. Broadway, Baltimore, MD 21205, USA.ORCID 0000-0002-2567-1658
Ralph H HrubanDepartment of Oncology, the Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine, 733 N. Broadway, Baltimore, MD 21205, USA.ORCID 0000-0003-4554-5672
Kenneth W KinzlerDepartment of Oncology, the Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine, 733 N. Broadway, Baltimore, MD 21205, USA. npapado1@jhmi.edu vogelbe@jhmi.edu kinzlke@jhmi.edu.ORCID 0000-0001-5591-1176
Bert VogelsteinDepartment of Oncology, the Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine, 733 N. Broadway, Baltimore, MD 21205, USA. npapado1@jhmi.edu vogelbe@jhmi.edu kinzlke@jhmi.edu.ORCID 0000-0003-0766-3854
Nickolas PapadopoulosDepartment of Oncology, the Sidney Kimmel Cancer Center, Johns Hopkins University School of Medicine, 733 N. Broadway, Baltimore, MD 21205, USA. npapado1@jhmi.edu vogelbe@jhmi.edu kinzlke@jhmi.edu.ORCID 0000-0001-7135-7451
Geisinger Medical Center · USJohns Hopkins University · USDetection Limit (United States) · USHoward Hughes Medical Institute · USEmory University · US
Funding
Translational Research Central ServicesP30CA006973 · NCI · JOHNS HOPKINS UNIVERSITY · PI WILLIAM George NELSON · 1985 to 2026
$208.6MTumor Antigens for Individual Signatures and TherapyP50CA062924 · NCI · JOHNS HOPKINS UNIVERSITY · PI JAFFEE, ELIZABETH M. · 1993 to 2022
$54.6MMEDICAL SCIENTIST TRAINING PROGRAMT32GM007309 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI COX, ANDREA L · 1985 to 2019
$43.2MSPORE in Ovarian CancerP50CA228991 · NCI · JOHNS HOPKINS UNIVERSITY · PI Ronny I DRAPKIN, IE-MING SHIH · 2018 to 2026
$20.5MMedical Scientist Training ProgramT32GM136577 · NIGMS · JOHNS HOPKINS UNIVERSITY · PI ANDREA L COX · 2020 to 2026
$13.4MRefinement and Discovery of Nuclear Matrix Protein Markers for Colorectal CancerU01CA152753 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KINZLER, KENNETH W., SCHOEN, ROBERT E. · 2010 to 2021
$6.8MMulti-analyte Approach for Earlier Detection of Cancers in Non Plasma BiofluidsU01CA230691 · NCI · JOHNS HOPKINS UNIVERSITY · PI Nishant Agrawal, CHETAN BETTEGOWDA · 2018 to 2026
$6.7MInterrogating malignant gliomas using released tumor DNA in cerebrospinal fluidR37CA230400 · NCI · JOHNS HOPKINS UNIVERSITY · PI BETTEGOWDA, CHETAN · 2018 to 2024
$2.6MGenetic Cytology for Ovarian and Endometrial Cancer ScreeningR44CA203350 · NCI · PAPGENE, INC. · PI KINDE, ISAAC A · 2016 to 2017
$2.3MMRgFUS-enabled non-invasive interrogation of malignant glioma via circulating tumor DNAR21NS113016 · NINDS · JOHNS HOPKINS UNIVERSITY · PI BETTEGOWDA, CHETAN, WOODWORTH, GRAEME F · 2019 to 2019
$454kNCI NIH HHS HHSN261201600034CNCI NIH HHS P30 CA006973NCI NIH HHS P50 CA062924NCI NIH HHS P50 CA228991NCI NIH HHS R37 CA230400NCI NIH HHS R44 CA203350NCI NIH HHS U01 CA152753NCI NIH HHS U01 CA230691NIGMS NIH HHS T32 GM007309NIGMS NIH HHS T32 GM136577NINDS NIH HHS R21 NS113016
Abstract
Cancer treatments are often more successful when the disease is detected early. We evaluated the feasibility and safety of multicancer blood testing coupled with positron emission tomography-computed tomography (PET-CT) imaging to detect cancer in a prospective, interventional study of 10,006 women not previously known to have cancer. Positive blood tests were independently confirmed by a diagnostic PET-CT, which also localized the cancer. Twenty-six cancers were detected by blood testing. Of these, 15 underwent PET-CT imaging and nine (60%) were surgically excised. Twenty-four additional cancers were detected by standard-of-care screening and 46 by neither approach. One percent of participants underwent PET-CT imaging based on false-positive blood tests, and 0.22% underwent a futile invasive diagnostic procedure. These data demonstrate that multicancer blood testing combined with PET-CT can be safely incorporated into routine clinical care, in some cases leading to surgery with intent to cure.
Indexed as
Hematologic TestsPositron Emission Tomography Computed TomographyAgedCohort StudiesEarly Detection of CancerFemaleHumansMass ScreeningNeoplasms
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.